Octreotide as a novel agent for the management of bronchorrhea in mechanically ventilated patients: A case series and review of literature

Sambhawana Bhandari; Oleg Sostin; Akash Shah; John Chronakos; Douglas Kahn; Jose Mendez; Abhijith Hegde

doi:10.1016/j.rmcr.2023.101891

Octreotide as a novel agent for the management of bronchorrhea in mechanically ventilated patients: A case series and review of literature

Sambhawana Bhandari
, Oleg Sostin
, Akash Shah
, John Chronakos
, Douglas Kahn
, Jose Mendez
, Abhijith Hegde

Division of Rheumatology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Excessive bronchial secretions pose a challenge in mechanically-ventilated patients and may prolong the time to extubation, increasing the risk for pneumonia. Octreotide, a somatostatin analog, has been used to decrease bronchial secretions especially for the symptomatic management of patients with lung cancer. We describe three patients in the form of a case series and discuss effect of octretotide on bronchial secretions and management of bronchorrhea in the intensive care unit. Similar to reports of its utilization in palliative care in patients with lung cancer, we observed a clinically significant decrease in the rate of bronchial secretions.

Original language	English
Article number	101891
Journal	Respiratory Medicine Case Reports
Volume	45
DOIs	https://doi.org/10.1016/j.rmcr.2023.101891
State	Published - Jan 2023

Keywords

Airway extubation
Mechanical ventilation
Octreotide
Ventilator associated pneumonia

Access to Document

10.1016/j.rmcr.2023.101891

Cite this

@article{32081923f92b4884b6e76a67bc140b06,

title = "Octreotide as a novel agent for the management of bronchorrhea in mechanically ventilated patients: A case series and review of literature",

abstract = "Excessive bronchial secretions pose a challenge in mechanically-ventilated patients and may prolong the time to extubation, increasing the risk for pneumonia. Octreotide, a somatostatin analog, has been used to decrease bronchial secretions especially for the symptomatic management of patients with lung cancer. We describe three patients in the form of a case series and discuss effect of octretotide on bronchial secretions and management of bronchorrhea in the intensive care unit. Similar to reports of its utilization in palliative care in patients with lung cancer, we observed a clinically significant decrease in the rate of bronchial secretions.",

keywords = "Airway extubation, Mechanical ventilation, Octreotide, Ventilator associated pneumonia",

author = "Sambhawana Bhandari and Oleg Sostin and Akash Shah and John Chronakos and Douglas Kahn and Jose Mendez and Abhijith Hegde",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = jan,

doi = "10.1016/j.rmcr.2023.101891",

language = "English",

volume = "45",

journal = "Respiratory Medicine Case Reports",

issn = "2213-0071",

}

TY - JOUR

T1 - Octreotide as a novel agent for the management of bronchorrhea in mechanically ventilated patients

T2 - A case series and review of literature

AU - Bhandari, Sambhawana

AU - Sostin, Oleg

AU - Shah, Akash

AU - Chronakos, John

AU - Kahn, Douglas

AU - Mendez, Jose

AU - Hegde, Abhijith

PY - 2023/1

Y1 - 2023/1

N2 - Excessive bronchial secretions pose a challenge in mechanically-ventilated patients and may prolong the time to extubation, increasing the risk for pneumonia. Octreotide, a somatostatin analog, has been used to decrease bronchial secretions especially for the symptomatic management of patients with lung cancer. We describe three patients in the form of a case series and discuss effect of octretotide on bronchial secretions and management of bronchorrhea in the intensive care unit. Similar to reports of its utilization in palliative care in patients with lung cancer, we observed a clinically significant decrease in the rate of bronchial secretions.

AB - Excessive bronchial secretions pose a challenge in mechanically-ventilated patients and may prolong the time to extubation, increasing the risk for pneumonia. Octreotide, a somatostatin analog, has been used to decrease bronchial secretions especially for the symptomatic management of patients with lung cancer. We describe three patients in the form of a case series and discuss effect of octretotide on bronchial secretions and management of bronchorrhea in the intensive care unit. Similar to reports of its utilization in palliative care in patients with lung cancer, we observed a clinically significant decrease in the rate of bronchial secretions.

KW - Airway extubation

KW - Mechanical ventilation

KW - Octreotide

KW - Ventilator associated pneumonia

UR - https://www.scopus.com/pages/publications/85164326991

U2 - 10.1016/j.rmcr.2023.101891

DO - 10.1016/j.rmcr.2023.101891

M3 - Article

AN - SCOPUS:85164326991

SN - 2213-0071

VL - 45

JO - Respiratory Medicine Case Reports

JF - Respiratory Medicine Case Reports

M1 - 101891

ER -

Octreotide as a novel agent for the management of bronchorrhea in mechanically ventilated patients: A case series and review of literature

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this